Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France

INTRODUCTION: The direct oral anticoagulant (DOAC) apixaban has shown to have non-inferior efficacy and better safety than vitamin K antagonists (VKAs) in patients with venous thromboembolism (VTE). We determined whether healthcare resource use (HCRU) and direct all-cause medical and non-medical cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokgokong, Ruth, Khachatryan, Artak, Quignot, Nadia, Chaves, Jose, Moniot, Audrey, Gusto, Gaelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309117/
https://www.ncbi.nlm.nih.gov/pubmed/35767124
http://dx.doi.org/10.1007/s12325-022-02200-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309117/
https://www.ncbi.nlm.nih.gov/pubmed/35767124
http://dx.doi.org/10.1007/s12325-022-02200-7

Ejemplares similares